TABLE 1.
Main features of the study patients
| Overall (n=1071) | Responders (n=173) | Non-responders (n=898) | p-value | |
| Male | 551 (52) | 82 (47) | 469 (52) | 0.27 |
| Age at transplantation (years) | 47 (31–58) | 32 (24–52) | 50 (34–58) | 0.001 |
| Age at vaccination (years) | 54 (40–63) | 45 (33–58) | 56 (43–64) | 0.002 |
| Transplantation indication | 0.0035 | |||
| CF | 327 (31) | 87 (50) | 240 (27) | |
| COPD | 323 (30) | 36 (21) | 287 (32) | |
| Fibrosis | 160 (15) | 13 (7) | 147 (16) | |
| PAH | 121 (11) | 18 (10) | 103 (11) | |
| Other | 140 (13) | 20 (11) | 120 (13) | |
| Transplantation procedure | 0.37 | |||
| Double lung | 918 (86) | 156 (90) | 762 (85) | |
| Single lung | 75 (7) | 9 (5) | 66 (7) | |
| Heart–lung | 62 (6) | 7 (4) | 55 (6) | |
| Multiorgan | 16 (1) | 2 (1) | 14 (2) | |
| Maintenance immunosuppression | ||||
| Cyclosporine | 197 (20) | 24 (15) | 173 (21) | 0.30 |
| Tacrolimus | 786 (79) | 132 (83) | 654 (78) | 0.49 |
| Corticosteroids | 903 (85) | 123 (71) | 780 (87) | 0.004 |
| Mycophenolate | 675 (63) | 89 (51) | 586 (66) | 0.03 |
| Azathioprine | 157 (15) | 36 (21) | 121 (14) | 0.15 |
| Everolimus | 195 (18) | 39 (23) | 156 (17) | 0.18 |
| Sirolimus | 11 (1) | 3 (2) | 8 (1) | 0.19 |
| Intensified immunosuppression within 6 months before vaccination (n=1064) | 90 (8) | 7 (4) | 83 (9) | 0.03 |
| Methylprednisolone | 52 (5) | 5 (3) | 47 (5) | 0.24 |
| Rituximab | 12 (1) | 0 (0) | 12 (1) | 0.24 |
| Anti-thymocyte globulins | 2 (0) | 0 | 2 (0) | 0.99 |
| Intravenous immunoglobulins | 25 (2) | 2 (1) | 23 (3) | 0.23 |
| Plasmapheresis | 1 (0) | 0 | 1 (0) | 0.99 |
| Follow-up (months) | 8.3 (6.7–9.3) | 8.6 (7.2–9.3) | 8.3 (6.7–9.3) | 0.08 |
| Death | 13 (1) | 0 | 13 (1) | 0.14 |
Data are presented as n (%) or median (interquartile range), unless otherwise stated. CF: cystic fibrosis; PAH: pulmonary arterial hypertension.